GENFIT S A/ADR (NASDAQ:GNFT) Given Average Recommendation of “Buy” by Brokerages

Shares of GENFIT S A/ADR (NASDAQ:GNFT) have been assigned an average recommendation of “Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $52.62.

Several brokerages have recently weighed in on GNFT. Roth Capital reiterated a “buy” rating on shares of GENFIT S A/ADR in a research report on Tuesday, April 23rd. Zacks Investment Research cut GENFIT S A/ADR from a “hold” rating to a “sell” rating in a research report on Tuesday, July 9th. Svb Leerink began coverage on GENFIT S A/ADR in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $58.00 price target for the company. Stifel Nicolaus began coverage on GENFIT S A/ADR in a research report on Tuesday, June 25th. They issued a “hold” rating for the company. Finally, Barclays began coverage on GENFIT S A/ADR in a research report on Monday, April 22nd. They issued an “overweight” rating and a $55.00 price target for the company.

A number of hedge funds have recently modified their holdings of the business. Boussard & Gavaudan Investment Management LLP bought a new stake in GENFIT S A/ADR during the second quarter worth about $199,000. One68 Global Capital LLC bought a new stake in GENFIT S A/ADR during the first quarter worth about $270,000. TT International bought a new stake in GENFIT S A/ADR during the first quarter worth about $1,200,000. Dean Capital Investments Management LLC bought a new stake in GENFIT S A/ADR during the first quarter worth about $650,000. Finally, Victory Capital Management Inc. bought a new stake in GENFIT S A/ADR during the first quarter worth about $2,358,000. 14.69% of the stock is owned by hedge funds and other institutional investors.



NASDAQ:GNFT traded up $0.45 during trading hours on Thursday, reaching $16.49. The stock had a trading volume of 125,425 shares, compared to its average volume of 109,644. The stock has a 50 day moving average of $18.30. GENFIT S A/ADR has a 12-month low of $15.92 and a 12-month high of $26.25.

About GENFIT S A/ADR

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Read More: What is Compound Annual Growth Rate (CAGR)?

Analyst Recommendations for GENFIT S A/ADR (NASDAQ:GNFT)

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.